ASCO Venous Thromboembolism Guidelines for Cancer Patients
For cancer-associated VTE treatment, use LMWH, apixaban, rivaroxaban, or edoxaban for at least 6 months as first-line therapy over vitamin K antagonists, but exercise caution with DOACs in gastrointestinal and genitourinary malignancies due to increased bleeding risk 1.
VTE Treatment in Cancer Patients
Initial Anticoagulation (First 5-10 Days)
For patients starting parenteral therapy 1:
- LMWH is preferred over unfractionated heparin
- Alternative options: UFH, fondaparinux, rivaroxaban, or apixaban
- Avoid LMWH if creatinine clearance <30 mL/min (severe renal impairment)
Long-Term Anticoagulation (≥6 Months)
Preferred agents 1:
- LMWH (dalteparin, enoxaparin)
- Direct oral anticoagulants: edoxaban, rivaroxaban, or apixaban
- Vitamin K antagonists only if LMWH or DOACs unavailable
Critical DOAC Considerations
Exercise extreme caution with DOACs in 1, 2:
- Gastrointestinal malignancies
- Genitourinary cancers
- Any high mucosal bleeding risk settings
The evidence shows DOACs reduce recurrent VTE compared to LMWH but increase clinically relevant non-major bleeding, particularly in GI cancers 2. The ADAM VTE trial demonstrated apixaban had lower recurrent VTE rates (0.7% vs 6.3%) compared to dalteparin, with minimal major bleeding 1.
Always assess drug-drug interactions before prescribing DOACs, especially with targeted cancer therapies 1.
VTE Prophylaxis Recommendations
Hospitalized Cancer Patients
Offer pharmacologic thromboprophylaxis to 2:
- Patients with active malignancy AND acute medical illness or reduced mobility
- Patients with active malignancy even without additional risk factors (if no bleeding contraindications)
Do NOT routinely give prophylaxis to 2:
- Patients admitted solely for minor procedures or chemotherapy infusion
- Stem-cell/bone marrow transplant recipients
Ambulatory Cancer Patients
Offer thromboprophylaxis with apixaban, rivaroxaban, or LMWH to selected high-risk outpatients receiving chemotherapy 2. This represents a major update from previous guidelines that discouraged DOAC use due to lack of cancer-specific data 3.
Surgical Cancer Patients
All patients undergoing major cancer surgery should receive prophylaxis 2:
- Start before surgery
- Continue for at least 7-10 days postoperatively
- Consider extended prophylaxis in select high-risk cases
Duration of Anticoagulation
Continue anticoagulation beyond 6 months in patients with active cancer 4. The definition of "active cancer" includes ongoing treatment, progressive disease, or metastatic disease. Reassess bleeding and thrombotic risk regularly throughout the cancer care pathway 4.
Algorithm for Anticoagulant Selection
Step 1: Assess bleeding risk
- GI or GU malignancy? → Prefer LMWH over DOACs
- Thrombocytopenia from chemotherapy? → LMWH preferred
- Low bleeding risk? → DOACs acceptable
Step 2: Evaluate renal function
- CrCl <30 mL/min? → Avoid LMWH, consider apixaban or rivaroxaban with dose adjustment
Step 3: Check drug interactions
- Strong CYP3A4 inhibitors/inducers with targeted therapy? → May preclude DOAC use
Step 4: Consider patient factors
- Preference for oral vs. subcutaneous administration
- Ability to afford medication
- Compliance with twice-daily (apixaban) vs. once-daily (rivaroxaban, edoxaban) dosing
Common Pitfalls to Avoid
- Do not use DOACs indiscriminately in GI cancers - the bleeding risk outweighs benefits in many cases 1
- Do not forget to reassess VTE and bleeding risk as cancer treatment evolves 4
- Do not stop anticoagulation at 6 months if cancer remains active 4
- Do not overlook drug-drug interactions between DOACs and cancer therapies 1